PERSISTENCE MECHANISMS IN PSEUDOMONAS-AERUGINOSA FROM CYSTIC-FIBROSIS PATIENTS UNDERGOING CIPROFLOXACIN THERAPY

被引:32
作者
DIVER, JM
SCHOLLAARDT, T
RABIN, HR
THORSON, C
BRYAN, LE
机构
[1] FOOTHILLS PROV GEN HOSP,CALGARY,ALBERTA,CANADA
[2] UNIV CALGARY,DEPT MED,CALGARY T2N 4N1,ALBERTA,CANADA
关键词
D O I
10.1128/AAC.35.8.1538
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The mechanisms of persistence to ciprofloxacin in nine sets of Pseudomonas aeruginosa strains isolated during ciprofloxacin therapy of chronic lung infections in cystic fibrosis patients were studied. Low to moderate levels of ciprofloxacin resistance developed in each case. Each set of pretherapy ciprofloxacin-susceptible, during-therapy ciprofloxacin-resistant, and posttherapy ciprofloxacin-susceptible isolates were shown to be genotypically related by using a radiolabeled epidemiological gene probe. All ciprofloxacin-resistant isolates were found to have altered susceptibilities to both nalidixic acid and various chemically unrelated antibiotics. Analysis of possible resistance mechanisms showed that the strains had altered outer membrane protein or lipopolysaccharide profiles. Complementation of possible DNA gyrase mutations with a plasmid-borne, wild-type Escherichia coli gyrA gene indicated that altered DNA gyrase was at least partly responsible for ciprofloxacin resistance in all strains tested. Attempts to generate ciprofloxacin-susceptible revertants in vitro showed that in some strains reversion was rapid in the absence of ciprofloxacin, while in other strains it was not possible to generate revertants. These data indicate that persistence of Pseudomonas aeruginosa to ciprofloxacin involves changes in DNA gyrase and is associated with pleiotropic changes in outer membrane proteins and lipopolysaccharide.
引用
收藏
页码:1538 / 1546
页数:9
相关论文
共 49 条
[11]   CIPROFLOXACIN THERAPY OF INFECTIONS CAUSED BY PSEUDOMONAS-AERUGINOSA AND OTHER RESISTANT-BACTERIA [J].
ERON, LJ ;
HARVEY, L ;
HIXON, DL ;
PORETZ, DM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (02) :308-310
[12]   USE OF CIPROFLOXACIN IN THE TREATMENT OF PSEUDOMONAS-AERUGINOSA INFECTIONS [J].
FOLLATH, F ;
BINDSCHEDLER, M ;
WENK, M ;
FREI, R ;
STALDER, H ;
REBER, H .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1986, 5 (02) :236-240
[13]   NEW NORFLOXACIN RESISTANCE GENE IN PSEUDOMONAS-AERUGINOSA PAO [J].
FUKUDA, H ;
HOSAKA, M ;
HIRAI, K ;
IYOBE, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (09) :1757-1761
[14]   DNA GYRASE - ENZYME THAT INTRODUCES SUPERHELICAL TURNS INTO DNA [J].
GELLERT, M ;
MIZUUCHI, K ;
ODEA, MH ;
NASH, HA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1976, 73 (11) :3872-3876
[15]   PENETRATION OF BETA-LACTAMS THROUGH PSEUDOMONAS-AERUGINOSA PORIN CHANNELS [J].
GODFREY, AJ ;
BRYAN, LE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (08) :1216-1221
[16]   SUBINHIBITORY ANTIBIOTICS REDUCE PSEUDOMONAS-AERUGINOSA TISSUE-INJURY IN THE RAT LUNG MODEL [J].
GRIMWOOD, K ;
TO, M ;
RABIN, HR ;
WOODS, DE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 24 (06) :937-945
[17]   OUTER-MEMBRANE PROTEINS OF PSEUDOMONAS [J].
HANCOCK, REW ;
SIEHNEL, R ;
MARTIN, N .
MOLECULAR MICROBIOLOGY, 1990, 4 (07) :1069-1075
[18]   ESCHERICHIA COLI K-12 MUTANTS RESISTANT TO NALIDIXIC ACID - GENETIC MAPPING AND DOMINANCE STUDIES [J].
HANE, MW ;
WOOD, TH .
JOURNAL OF BACTERIOLOGY, 1969, 99 (01) :238-&
[19]   ISOLATION OF LARGE BACTERIAL PLASMIDS AND CHARACTERIZATION OF P2 I COMPATIBILITY GROUP PLASMIDS PMG1 AND PMG5 [J].
HANSEN, JB ;
OLSEN, RH .
JOURNAL OF BACTERIOLOGY, 1978, 135 (01) :227-238
[20]   MUTATIONS PRODUCING RESISTANCE TO NORFLOXACIN IN PSEUDOMONAS-AERUGINOSA [J].
HIRAI, K ;
SUZUE, S ;
IRIKURA, T ;
IYOBE, S ;
MITSUHASHI, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (04) :582-586